Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nezulcitinib - Theravance Biopharma

Next Previous
Search
Drug Profile

Nezulcitinib - Theravance Biopharma

Alternative Names: TD-0903; THRX-136377

Latest Information Update: 22 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theravance Biopharma
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Azetidines; Imidazoles; Indazoles; Ketones; Pyridines; Small molecules
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute lung injury

Most Recent Events

  • 09 Sep 2023 Pharmacodynamics data from preclinical studies in Acute lung injury presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
  • 03 Mar 2023 Nezulcitinib - Theravance Biopharma is available for licensing as of 27 Feb 2023. https://www.theravance.com/
  • 27 Feb 2023 Discontinued - Phase-II for Acute lung injury (In the elderly, Adjuvant therapy, In adults) in United Kingdom, Moldova, Romania, Ukraine, Finland, USA, Argentina, South Africa, Brazil (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top